Development and Validation of a Sensitive LC–MS/MS Method for Determination of Lenvatinib and Its Major Metabolites in Human Plasma and Its Application in Hepatocellular Carcinoma Patients
Journal of Separation Science · 2024
DOI: 10.1002/jssc.70042 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Separation Science, 2024. Verfasst von Shaoxing Guan und 6 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-M…. Hauptthemen laut MEDLINE: Quinolines, Carcinoma, Hepatocellular, Phenylurea Compounds, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Natural Science Foundation of China, Shenzhen Science and Technology Program, Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program.
Abstract (Originalsprache)
Lenvatinib has been demonstrated effective in advanced hepatocellular carcinoma (HCC), but the pharmacokinetic–pharmacodynamics behavior of lenvatinib and its metabolites remains unclear. To investigate the pharmacokinetic–pharmacodynamics behavior of lenvatinib and its active metabolites in advanced HCC patients, it is important to develop a simple and rapid method to analyze the exposures of lenvatinib and its metabolites in human samples. Here, we established and validated a simple and rapid method for determining lenvatinib and its three major metabolites, descyclopropyl lenvatinib (M1), O‐demethyl lenvatinib hydrochloride (M2), and lenvatinib N‐Oxide (M3) by liquid chromatography‐tandem mass spectrometry method. Lenvatinib and its main metabolites were separated on an X‐Terra RP18 column (50 × 2.1 mm, 3.5 µm) at 35°C within 3 min, and the analytes were isocratically eluted with the mobile phase of methanol–water (10:90, v/v) containing 0.1% of formic acid at a flow rate of 0.15 mL/min. The calibration range was 1–1000 ng/mL for lenvatinib, while 0.1–100 ng/mL for M1–M3 under positive electrospray ionization mode. The inter‐ and intra‐batch precisions and accuracy were acceptable for lenvatinib and its metabolites. This method was successfully applied to measure lenvatinib and its metabolites in plasma samples from HCC patients, which provides a robust tool for pharmacokinetic–pharmacodynamics studies of lenvatinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
ORCID-Profile: Huichang Bi
Förderung
- Natural Science Foundation of China
- Shenzhen Science and Technology Program
- Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
- Science and Technology Innovation National Engineering and Technology Research Center for New drug Druggability Evaluation
- Science and Technology Innovation Project of Guangdong Medical Products Administration
- Guangdong Medical Research Foundation
- Guangdong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
Zitieren
APA
Guan, S., Yuan, G., Bi, G., Yu, Q., Fang, J. H., Chen, J., & Bi, H. (2024). Development and Validation of a Sensitive LC–MS/MS Method for Determination of Lenvatinib and Its Major Metabolites in Human Plasma and Its Application in Hepatocellular Carcinoma Patients. Journal of Separation Science. https://doi.org/10.1002/jssc.70042
Vancouver
Guan S, Yuan G, Bi G, Yu Q, Fang JH, Chen J, et al. Development and Validation of a Sensitive LC–MS/MS Method for Determination of Lenvatinib and Its Major Metabolites in Human Plasma and Its Application in Hepatocellular Carcinoma Patients. Journal of Separation Science. 2024. doi:10.1002/jssc.70042
BibTeX
@article{Guan2024,
author = {Guan, Shaoxing and Yuan, Guosheng and Bi, Guofang and Yu, Qingqing and Fang, Jian-Hong and Chen, Jinzhang and Bi, Huichang},
title = {Development and Validation of a Sensitive LC–MS/MS Method for Determination of Lenvatinib and Its Major Metabolites in Human Plasma and Its Application in Hepatocellular Carcinoma Patients},
journal = {Journal of Separation Science},
year = {2024},
doi = {10.1002/jssc.70042}
}
EUVIMED